View Future GrowthProactis 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Proactis 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Software 산업 성장률15.21%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Jan 2024최근 과거 실적 업데이트공시 • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025공시 • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024Reported Earnings • Jan 15Full year 2022 earnings releasedFull year 2022 results: Revenue: €14.4m (up 28% from FY 2021). Net income: €290.0k (up €816.0k from FY 2021). Profit margin: 2.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.공시 • Jan 12+ 1 more updateProactis SA to Report Fiscal Year 2022 Results on Jan 12, 2023Proactis SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Jan 12, 2023Reported Earnings • May 02First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €659.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021).Reported Earnings • Dec 03Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €11.2m (down 9.7% from FY 2020). Net loss: €526.0k (loss narrowed 95% from FY 2020). Revenue was in line with analyst estimates.모든 업데이트 보기Recent updates공시 • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.New Risk • Apr 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2024 fiscal period end). Share price has been highly volatile over the past 3 months (36% average weekly change). Market cap is less than US$10m (€5.42m market cap, or US$6.34m).Buy Or Sell Opportunity • Apr 21Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.1% to €0.043. The fair value is estimated to be €0.055, however this is not to be taken as a buy recommendation but rather should be used as a guide only.New Risk • Apr 19New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€5.96m market cap, or US$7.01m).New Risk • Feb 01New major risk - Revenue and earnings growthRevenue has declined by 22% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue has declined by 22% over the past year. Market cap is less than US$10m (€6.57m market cap, or US$7.79m). Minor Risk Negative equity (-€947k).공시 • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.분석 기사 • Dec 05Proactis SA's (EPA:PROAC) Share Price Boosted 50% But Its Business Prospects Need A Lift TooProactis SA ( EPA:PROAC ) shares have had a really impressive month, gaining 50% after a shaky period beforehand. While...분석 기사 • Oct 10Lacklustre Performance Is Driving Proactis SA's (EPA:PROAC) Low P/SYou may think that with a price-to-sales (or "P/S") ratio of 0.8x Proactis SA ( EPA:PROAC ) is a stock worth checking...공시 • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025공시 • Sep 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 31st of August 2025, Mrs. Maria LARSEN was co-opted as a director to replace Mrs. Lucy FOX, who resigned. Shareholders will be asked to approve this appointment at the next Annual General Meeting called to approve the financial statements. Maria LARSEN joined the PROACTIS Group in April 2025 as Customer Success and Transformation Director. Maria's diverse career spans leadership roles within the British Army, humanitarian aid and transformational management consultancy. She brings exceptional leadership experience and a deep passion for stakeholder engagement. Maria LARSEN has delivered high-impact solutions for the private sector, third sector, the MoD, DHSC, and other public sector organizations. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028, Bonnie MITCHELL: Director: Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Graham DAVIS:Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.New Risk • Jul 31New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€8.33m market cap, or US$9.53m).공시 • Jul 02Proactis SA Approves Resignation of Monsieur Adrian MCSHANE-CHAPMAN as DirectorUnder the terms of the Board of Directors of the company PROACTIS SA held on the 25 June, Mr. Monsieur Adrian MCSHANE-CHAPMAN, resigning.New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 15% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported January 2024 fiscal period end). Market cap is less than US$100m (€8.87m market cap, or US$10.2m).New Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 15% over the past year. Market cap is less than US$10m (€8.13m market cap, or US$9.02m). Minor Risks Latest financial reports are more than 6 months old (reported January 2024 fiscal period end). Share price has been volatile over the past 3 months (9.7% average weekly change).New Risk • Feb 06New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (€9.41m market cap, or US$9.76m).분석 기사 • Jan 18Benign Growth For Proactis SA (EPA:PROAC) Underpins Its Share PriceProactis SA's ( EPA:PROAC ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now compared to...New Risk • Oct 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.01m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€9.01m market cap, or US$9.85m).분석 기사 • Oct 04The Market Doesn't Like What It Sees From Proactis SA's (EPA:PROAC) Revenues YetProactis SA's ( EPA:PROAC ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now compared to...공시 • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024분석 기사 • May 24Estimating The Fair Value Of Proactis SA (EPA:PROAC)Key Insights The projected fair value for Proactis is €0.059 based on 2 Stage Free Cash Flow to Equity Current share...New Risk • Apr 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2023 fiscal period end). Share price has been highly volatile over the past 3 months (25% average weekly change). Revenue has declined by 12% over the past year. Minor Risk Market cap is less than US$100m (€9.75m market cap, or US$10.4m).Buy Or Sell Opportunity • Apr 11Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 48% to €0.043. The fair value is estimated to be €0.059, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Mar 26Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 45% to €0.045. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Mar 04Now 29% undervalued after recent price dropOver the last 90 days, the stock has fallen 46% to €0.041. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Feb 01Now 42% overvalued after recent price riseOver the last 90 days, the stock has risen 6.1% to €0.079. The fair value is estimated to be €0.055, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.분석 기사 • Jan 31A Look At The Intrinsic Value Of Proactis SA (EPA:PROAC)Key Insights Proactis' estimated fair value is €0.055 based on 2 Stage Free Cash Flow to Equity Current share price of...New Risk • Jan 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.13m (US$8.81m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 11% per year over the past 5 years. Market cap is less than US$10m (€8.13m market cap, or US$8.81m). Minor Risk Latest financial reports are more than 6 months old (reported January 2023 fiscal period end).New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 11% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported January 2023 fiscal period end). Market cap is less than US$100m (€11.5m market cap, or US$12.5m).공시 • May 23Proactis SA Announces Directorate ChangesProactis SA announced that under the terms of the general meeting of the company which took place on the 22 May 2023, Lucy FOX and Adrian MCSHANE-CHAPMAN have been appointed directors of PROACTIS SA, for a period of six (6) years. Lucy FOX joined the Proactis group as Chief Commercial Officer in January 2023 to improve the group's commercial growth. Adrian MCSHANE-CHAPMAN joined the Proactis group in April 2022 as Human Resources Manager in the United Kingdom, before being appointed Group People Services Lead. His mission is to make Proactis a career partner for employees by supporting them throughout their career within the company. In addition, Richard HUGHES and Rachel ROLLINSON have tendered their resignation from their role of directors of PROACTIS SA as of May 23, 2023. As a result of these changes, the Board of Directors of PROACTIS SA is made up of three members: Stephen LINE, Lucy FOX, and Adrian MCSHANE-CHAPMAN. The term of their mandate is expiring at the end of the shareholders meeting which will decide on the accounts for the 2028 financial year.Reported Earnings • Jan 15Full year 2022 earnings releasedFull year 2022 results: Revenue: €14.4m (up 28% from FY 2021). Net income: €290.0k (up €816.0k from FY 2021). Profit margin: 2.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.공시 • Jan 12+ 1 more updateProactis SA to Report Fiscal Year 2022 Results on Jan 12, 2023Proactis SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Jan 12, 2023분석 기사 • Dec 02Calculating The Intrinsic Value Of Proactis SA (EPA:PROAC)How far off is Proactis SA ( EPA:PROAC ) from its intrinsic value? Using the most recent financial data, we'll take a...Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CFO & Director Richard Hughes was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Oct 04Proactis (EPA:PROAC) Shareholders Will Want The ROCE Trajectory To ContinueTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...분석 기사 • Aug 09Estimating The Intrinsic Value Of Proactis SA (EPA:PROAC)Does the August share price for Proactis SA ( EPA:PROAC ) reflect what it's really worth? Today, we will estimate the...분석 기사 • May 18Proactis (EPA:PROAC) Is Looking To Continue Growing Its Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Reported Earnings • May 02First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €659.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021).Board Change • Apr 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CFO & Director Richard Hughes was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Feb 20We're Not Worried About Proactis' (EPA:PROAC) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Reported Earnings • Dec 03Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €11.2m (down 9.7% from FY 2020). Net loss: €526.0k (loss narrowed 95% from FY 2020). Revenue was in line with analyst estimates.분석 기사 • Oct 28Returns Are Gaining Momentum At Proactis (EPA:PROAC)There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...분석 기사 • May 28There's Been No Shortage Of Growth Recently For Proactis' (EPA:PROAC) Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term? One...분석 기사 • Feb 12Will Proactis' (EPA:PROAC) Growth In ROCE Persist?Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...Reported Earnings • Dec 03Full year 2020 earnings released: €0.07 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: €12.4m (down 15% from FY 2019). Net loss: €9.77m (down €10.7m from profit in FY 2019).매출 및 비용 세부 내역Proactis가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ENXTPA:PROAC 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Jan 2412-110031 Jan 2314-10031 Oct 221400031 Jul 221400030 Apr 221500031 Jan 221600031 Oct 211600031 Jul 2115-10030 Apr 2114-50031 Jan 2112-100031 Oct 2012-100031 Jul 2012-100030 Apr 2013-5-1031 Jan 20131-1031 Oct 19141-1031 Jul 191510031 Jan 191611031 Oct 181710031 Jul 181720030 Jun 171910031 Mar 172010031 Dec 162111030 Sep 1622-11030 Jun 1623-41031 Mar 1624-121031 Dec 1524-200030 Sep 1526-260030 Jun 1527-3100양질의 수익: PROAC가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 PROAC의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 PROAC의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: PROAC의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: PROAC의 지난 해 수익 증가율이 Software 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: PROAC는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YSoftware 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/18 20:21종가2026/05/18 00:00수익2024/01/31연간 수익2024/01/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Proactis SA는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025
공시 • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024
Reported Earnings • Jan 15Full year 2022 earnings releasedFull year 2022 results: Revenue: €14.4m (up 28% from FY 2021). Net income: €290.0k (up €816.0k from FY 2021). Profit margin: 2.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.
공시 • Jan 12+ 1 more updateProactis SA to Report Fiscal Year 2022 Results on Jan 12, 2023Proactis SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Jan 12, 2023
Reported Earnings • May 02First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €659.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021).
Reported Earnings • Dec 03Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €11.2m (down 9.7% from FY 2020). Net loss: €526.0k (loss narrowed 95% from FY 2020). Revenue was in line with analyst estimates.
공시 • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
New Risk • Apr 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2024 fiscal period end). Share price has been highly volatile over the past 3 months (36% average weekly change). Market cap is less than US$10m (€5.42m market cap, or US$6.34m).
Buy Or Sell Opportunity • Apr 21Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.1% to €0.043. The fair value is estimated to be €0.055, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
New Risk • Apr 19New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€5.96m market cap, or US$7.01m).
New Risk • Feb 01New major risk - Revenue and earnings growthRevenue has declined by 22% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue has declined by 22% over the past year. Market cap is less than US$10m (€6.57m market cap, or US$7.79m). Minor Risk Negative equity (-€947k).
공시 • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
분석 기사 • Dec 05Proactis SA's (EPA:PROAC) Share Price Boosted 50% But Its Business Prospects Need A Lift TooProactis SA ( EPA:PROAC ) shares have had a really impressive month, gaining 50% after a shaky period beforehand. While...
분석 기사 • Oct 10Lacklustre Performance Is Driving Proactis SA's (EPA:PROAC) Low P/SYou may think that with a price-to-sales (or "P/S") ratio of 0.8x Proactis SA ( EPA:PROAC ) is a stock worth checking...
공시 • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025
공시 • Sep 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 31st of August 2025, Mrs. Maria LARSEN was co-opted as a director to replace Mrs. Lucy FOX, who resigned. Shareholders will be asked to approve this appointment at the next Annual General Meeting called to approve the financial statements. Maria LARSEN joined the PROACTIS Group in April 2025 as Customer Success and Transformation Director. Maria's diverse career spans leadership roles within the British Army, humanitarian aid and transformational management consultancy. She brings exceptional leadership experience and a deep passion for stakeholder engagement. Maria LARSEN has delivered high-impact solutions for the private sector, third sector, the MoD, DHSC, and other public sector organizations. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028, Bonnie MITCHELL: Director: Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Graham DAVIS:Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
New Risk • Jul 31New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€8.33m market cap, or US$9.53m).
공시 • Jul 02Proactis SA Approves Resignation of Monsieur Adrian MCSHANE-CHAPMAN as DirectorUnder the terms of the Board of Directors of the company PROACTIS SA held on the 25 June, Mr. Monsieur Adrian MCSHANE-CHAPMAN, resigning.
New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 15% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported January 2024 fiscal period end). Market cap is less than US$100m (€8.87m market cap, or US$10.2m).
New Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 15% over the past year. Market cap is less than US$10m (€8.13m market cap, or US$9.02m). Minor Risks Latest financial reports are more than 6 months old (reported January 2024 fiscal period end). Share price has been volatile over the past 3 months (9.7% average weekly change).
New Risk • Feb 06New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (€9.41m market cap, or US$9.76m).
분석 기사 • Jan 18Benign Growth For Proactis SA (EPA:PROAC) Underpins Its Share PriceProactis SA's ( EPA:PROAC ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now compared to...
New Risk • Oct 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.01m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€9.01m market cap, or US$9.85m).
분석 기사 • Oct 04The Market Doesn't Like What It Sees From Proactis SA's (EPA:PROAC) Revenues YetProactis SA's ( EPA:PROAC ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now compared to...
공시 • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024
분석 기사 • May 24Estimating The Fair Value Of Proactis SA (EPA:PROAC)Key Insights The projected fair value for Proactis is €0.059 based on 2 Stage Free Cash Flow to Equity Current share...
New Risk • Apr 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2023 fiscal period end). Share price has been highly volatile over the past 3 months (25% average weekly change). Revenue has declined by 12% over the past year. Minor Risk Market cap is less than US$100m (€9.75m market cap, or US$10.4m).
Buy Or Sell Opportunity • Apr 11Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 48% to €0.043. The fair value is estimated to be €0.059, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Mar 26Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 45% to €0.045. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Mar 04Now 29% undervalued after recent price dropOver the last 90 days, the stock has fallen 46% to €0.041. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Feb 01Now 42% overvalued after recent price riseOver the last 90 days, the stock has risen 6.1% to €0.079. The fair value is estimated to be €0.055, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.
분석 기사 • Jan 31A Look At The Intrinsic Value Of Proactis SA (EPA:PROAC)Key Insights Proactis' estimated fair value is €0.055 based on 2 Stage Free Cash Flow to Equity Current share price of...
New Risk • Jan 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.13m (US$8.81m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 11% per year over the past 5 years. Market cap is less than US$10m (€8.13m market cap, or US$8.81m). Minor Risk Latest financial reports are more than 6 months old (reported January 2023 fiscal period end).
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 11% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported January 2023 fiscal period end). Market cap is less than US$100m (€11.5m market cap, or US$12.5m).
공시 • May 23Proactis SA Announces Directorate ChangesProactis SA announced that under the terms of the general meeting of the company which took place on the 22 May 2023, Lucy FOX and Adrian MCSHANE-CHAPMAN have been appointed directors of PROACTIS SA, for a period of six (6) years. Lucy FOX joined the Proactis group as Chief Commercial Officer in January 2023 to improve the group's commercial growth. Adrian MCSHANE-CHAPMAN joined the Proactis group in April 2022 as Human Resources Manager in the United Kingdom, before being appointed Group People Services Lead. His mission is to make Proactis a career partner for employees by supporting them throughout their career within the company. In addition, Richard HUGHES and Rachel ROLLINSON have tendered their resignation from their role of directors of PROACTIS SA as of May 23, 2023. As a result of these changes, the Board of Directors of PROACTIS SA is made up of three members: Stephen LINE, Lucy FOX, and Adrian MCSHANE-CHAPMAN. The term of their mandate is expiring at the end of the shareholders meeting which will decide on the accounts for the 2028 financial year.
Reported Earnings • Jan 15Full year 2022 earnings releasedFull year 2022 results: Revenue: €14.4m (up 28% from FY 2021). Net income: €290.0k (up €816.0k from FY 2021). Profit margin: 2.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.
공시 • Jan 12+ 1 more updateProactis SA to Report Fiscal Year 2022 Results on Jan 12, 2023Proactis SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Jan 12, 2023
분석 기사 • Dec 02Calculating The Intrinsic Value Of Proactis SA (EPA:PROAC)How far off is Proactis SA ( EPA:PROAC ) from its intrinsic value? Using the most recent financial data, we'll take a...
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CFO & Director Richard Hughes was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Oct 04Proactis (EPA:PROAC) Shareholders Will Want The ROCE Trajectory To ContinueTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
분석 기사 • Aug 09Estimating The Intrinsic Value Of Proactis SA (EPA:PROAC)Does the August share price for Proactis SA ( EPA:PROAC ) reflect what it's really worth? Today, we will estimate the...
분석 기사 • May 18Proactis (EPA:PROAC) Is Looking To Continue Growing Its Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Reported Earnings • May 02First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €659.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021).
Board Change • Apr 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CFO & Director Richard Hughes was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Feb 20We're Not Worried About Proactis' (EPA:PROAC) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Reported Earnings • Dec 03Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €11.2m (down 9.7% from FY 2020). Net loss: €526.0k (loss narrowed 95% from FY 2020). Revenue was in line with analyst estimates.
분석 기사 • Oct 28Returns Are Gaining Momentum At Proactis (EPA:PROAC)There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...
분석 기사 • May 28There's Been No Shortage Of Growth Recently For Proactis' (EPA:PROAC) Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
분석 기사 • Feb 12Will Proactis' (EPA:PROAC) Growth In ROCE Persist?Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
Reported Earnings • Dec 03Full year 2020 earnings released: €0.07 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: €12.4m (down 15% from FY 2019). Net loss: €9.77m (down €10.7m from profit in FY 2019).